BioXcel Falls 74.8% as Teva Bids $57.5 Million in Bankruptcy

BioXcel Therapeutics (BTAI) filed for bankruptcy and named Teva Pharmaceutical as stalking horse bidder for its neuroscience portfolio at $57.5 million upfront, sending BTAI shares down 74.76% to 0.18 at the Aug. 28, 2026 close.

BioXcel Therapeutics (BTAI) has filed for bankruptcy and arranged what the industry calls a stalking horse bid: Teva Pharmaceutical (TEVA) has agreed to acquire the company's neuroscience portfolio for $57.5 million upfront, subject to a court-supervised auction. Equity holders reacted the way equity holders usually do when a biotech's assets are put on the block at a fixed opening price. BTAI closed at 0.18, down 74.76% from the prior close of 0.72, with a session range of 0.16 to 0.23.

The news was reported by Fierce Biotech.

What a stalking horse bid actually commits Teva to

A stalking horse bidder is the first buyer through the door in a Chapter 11 asset sale. It negotiates the purchase agreement, sets the floor price, and accepts that the deal will be shopped to other bidders in a court-run auction. In exchange, the stalking horse typically gets deal protections — most commonly a break fee and expense reimbursement if it is outbid — and, crucially, it gets to define the shape of the transaction: which assets are included, which liabilities are left behind, and what the closing conditions look like.

For Teva, that is a low-risk way to look at a neuroscience portfolio. The $57.5 million upfront figure is the announced consideration; whether the final price is higher depends entirely on whether a rival bidder shows up at the auction. If none does, Teva buys at its own number. If one does, Teva either raises or walks away compensated. Either outcome is defensible for an acquirer that is not obliged to win.

Teva shares closed at 36.44, down 3.14% on the day from a prior close of 37.62, in a session where the broad market also drifted lower. The S&P 500 tracker SPY finished at $769.35, off 0.23%, the Nasdaq 100 proxy QQQ at $716.43, down 0.65%, and the Dow tracker DIA at $535.06, essentially flat at -0.03%. In other words, Teva's move was worse than the tape, but a $57.5 million upfront commitment is not the sort of number that moves a company of Teva's scale on its own. Investors reading that decline as a verdict on the bid are probably reading too much into it.

Why the neuroscience assets are the part worth buying

BioXcel built itself around central nervous system work — its lead franchise is a dexmedetomidine-based product for acute agitation, a sedative repositioned into a psychiatric setting. That is the type of asset that fits awkwardly inside a small, cash-hungry development company and comfortably inside a large generics-and-specialty platform. The hard part for a company like BioXcel was never the molecule. It was paying for a salesforce, funding label-expansion trials, and servicing debt while doing both.

Teva already carries a commercial neuroscience and CNS presence and a distribution footprint that a standalone small-cap cannot replicate. Bolting on an approved acute-agitation product costs it comparatively little in incremental infrastructure. That asymmetry — an asset worth more inside a big commercial machine than outside it — is the standard economic logic of a distressed biotech carve-out, and it is why the upfront price can look modest relative to what the underlying program cost to develop.

Where common shareholders sit in the queue

The 74.76% single-day decline in BTAI is not an overreaction so much as a repricing to what equity is realistically worth in a Chapter 11 asset sale. Bankruptcy has an order of payment: secured creditors first, then unsecured creditors, then preferred, then common stock. Sale proceeds and remaining cash flow up that ladder, and common holders receive something only if everything above them is made whole. In a filing where the headline asset sale is $57.5 million upfront, that is a demanding condition.

76% single-day decline in BTAI is not an overreaction so much as a repricing to what equity is realistically worth in a Chapter 11 asset sale.

What holders should track from here is narrow and specific:

Whether a competing bidder emerges. A contested auction raises the price and is the only mechanism that improves the recovery pool.
Bid procedures and the auction timetable as approved by the court, including the size of any break fee payable to Teva.
Which liabilities Teva is assuming versus leaving in the estate — that split determines how much of the purchase price is actually available to creditors.
Whether milestone or contingent payments sit behind the upfront figure, which would change the total value of the transaction without changing the day-one cash.
Any court-appointed equity committee, an unusual but not unheard-of sign that common holders are being taken seriously.

A familiar exit for a single-asset CNS story

BioXcel's path is the recognizable arc of a clinical-stage company that got a product approved and then discovered that approval is the beginning of the capital requirement rather than the end of it. Financing windows for small-cap biotech have been unforgiving, and a company with one commercial franchise, high fixed costs and debt has few levers when the equity market closes. The bankruptcy route, with a pre-negotiated buyer, is often the most orderly way to preserve the asset — the drug keeps being made and prescribed — even as the corporate shell around it is dismantled.

For the wider sector, the read-through is about pricing rather than science. When large pharmaceutical companies can acquire an approved CNS product through a bankruptcy court rather than a competitive licensing negotiation, it sets a reference point that other small-caps will be measured against. Distressed acquisitions are cheap because the seller has no alternative, and every such transaction reinforces the incentive for acquirers to wait rather than pay up earlier in the cycle.

What to watch next

The near-term calendar belongs to the court. Bid procedures need approval, an auction date needs setting, and any rival bidders need to qualify. Teva, meanwhile, has bought itself an option: it is the presumptive winner at a known price, with protections if it loses. That is a comfortable position, and it explains why acquirers increasingly prefer to be the stalking horse rather than the challenger.

Prices cited are the most recent closes as of 20:00 GMT on Aug. 28, 2026, with the market closed.

Key facts

BTAI last close: 0.18, -74.76% (as of 20:00 GMT, Aug. 28, 2026)
TEVA last close: 36.44, -3.14% (as of 20:00 GMT, Aug. 28, 2026)
Upfront deal value: $57.5 million for BioXcel's neuroscience portfolio
Deal structure: Teva as stalking horse bidder in a bankruptcy asset sale

Frequently asked questions

What did Teva agree to buy from BioXcel?

Teva Pharmaceutical agreed to acquire BioXcel Therapeutics' neuroscience portfolio for $57.5 million upfront. The agreement was struck alongside BioXcel's bankruptcy filing, and Teva is serving as the stalking horse bidder, meaning its offer sets the floor price in a court-supervised auction that other bidders may join.

What is a stalking horse bidder?

A stalking horse is the first buyer to sign a purchase agreement in a bankruptcy asset sale. It sets the minimum price and defines which assets and liabilities are included. In return it usually receives deal protections such as a break fee if a rival bidder wins the subsequent court-run auction.

How far did BioXcel shares fall?

BTAI closed at 0.18, down 74.76% from the previous close of 0.72, with a day range of 0.16 to 0.23, as of the last trade at 20:00 GMT on Aug. 28, 2026. The decline reflects the reality that common equity ranks last in a bankruptcy distribution.

Do BioXcel shareholders get anything?

Not necessarily. In Chapter 11, sale proceeds go to secured creditors first, then unsecured creditors, then preferred holders, with common stock last. Common shareholders recover value only if all claims above them are satisfied in full, which is a high bar when the headline asset sale is $57.5 million upfront.

How did Teva stock react?

Teva closed at 36.44, down 3.14% from a prior close of 37.62, in a session where the broad market was also lower — SPY off 0.23%, QQQ down 0.65% and DIA effectively flat. A $57.5 million upfront commitment is small relative to Teva's size, so the move is unlikely to be attributable to the bid alone.

Could another buyer outbid Teva?

Yes. The purpose of a stalking horse arrangement is to establish a floor and then market the assets. If a qualified rival bidder emerges at the court-approved auction, the price can rise, which is the main mechanism that would increase the pool available to BioXcel's creditors and, in turn, to any residual equity claims.

Sources

Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio — Fierce Biotech

Photo: Jess Loiterton · Pexels Licence — source